Enveric Biosciences Inc (ENVB)

$1.90 -0.02 (-1.04%)
Market Cap 2.64M
Revenue (ttm) 0.00
Net Income (ttm) -9.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 22,500
Avg Vol 434,406
Day's Range N/A - N/A
Shares Out 1.39M
Stochastic %K 21%
Beta 0.31
Analysts Strong Buy
Price Target $10.00

Company Profile

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules...

Industry: Biotechnology
Sector: Healthcare
Address:
245 First Street, Riverview II 18 th Floor, Cambridge, United States
Luckyjs38
Luckyjs38 Mar. 13 at 1:37 PM
$ENVB Its time to load up HODL IND filing imminent EB-003 is the way
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 11 at 8:48 PM
$ENVB lil tweak to u for later i
0 · Reply
Luckyjs38
Luckyjs38 Mar. 11 at 4:12 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Mar. 11 at 2:34 PM
$ENVB its time to load up in my opinion. trading at below its cash on hand to its equivalent market cap ⛓️‍💥🐦‍🔥♾️
0 · Reply
Luckyjs38
Luckyjs38 Mar. 10 at 3:17 PM
$ENVB Nows the time to load up and hold. I believe the IND filing will send it I know what I hold . do you ?
1 · Reply
Luckyjs38
Luckyjs38 Mar. 9 at 2:12 PM
$SPY $IWM $ENVB
0 · Reply
Luckyjs38
Luckyjs38 Mar. 9 at 1:56 PM
$SPY $IWM $ENVB ⛓️‍💥🐦‍🔥♾️ This company is extremely undervalued trading at a market cap of below cash on hand! My opinion EB-003 will change the medical science communities consensus on how to treat depression, anxiety,ptsd ect. 🇺🇸❤️🌎
0 · Reply
Luckyjs38
Luckyjs38 Mar. 6 at 10:03 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Mar. 6 at 7:55 PM
$ENVB @Enveric_Bio File the IND release the Kraken EB-003 LFG DR.TUCKER 🇺🇸
0 · Reply
topstockalerts
topstockalerts Mar. 6 at 2:23 PM
Pre Market Top Gainers $ASPC $ASPCU $ENVB $BEAT $HSPOU
0 · Reply
Latest News on ENVB
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Feb 25, 2026, 8:00 AM EST - 18 days ago

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Feb 19, 2026, 8:00 AM EST - 24 days ago

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Jan 29, 2026, 8:00 AM EST - 6 weeks ago

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jan 28, 2026, 5:00 PM EST - 6 weeks ago

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jan 28, 2026, 8:00 AM EST - 6 weeks ago

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences Announces Patent Issuance

Dec 29, 2025, 8:00 AM EST - 2 months ago

Enveric Biosciences Announces Patent Issuance

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 12, 2025, 4:46 PM EST - 3 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 11, 2025, 1:43 PM EST - 3 months ago

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Dec 9, 2025, 8:00 AM EST - 3 months ago

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Dec 4, 2025, 8:00 AM EST - 3 months ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Nov 26, 2025, 8:00 AM EST - 3 months ago

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Nov 14, 2025, 4:05 PM EST - 4 months ago

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Enveric Biosciences Announces Reverse Stock Split

Oct 23, 2025, 8:00 AM EDT - 5 months ago

Enveric Biosciences Announces Reverse Stock Split

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Oct 16, 2025, 8:30 AM EDT - 5 months ago

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Oct 15, 2025, 8:00 AM EDT - 5 months ago

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Oct 14, 2025, 9:00 AM EDT - 5 months ago

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Oct 2, 2025, 8:45 AM EDT - 5 months ago

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 18, 2025, 4:30 PM EDT - 6 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 9:24 AM EDT - 6 months ago

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Sep 17, 2025, 8:00 AM EDT - 6 months ago

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Sep 16, 2025, 8:45 AM EDT - 6 months ago

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 6 months ago

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Sep 2, 2025, 8:30 AM EDT - 6 months ago

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Aug 28, 2025, 8:30 AM EDT - 7 months ago

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Aug 14, 2025, 8:00 AM EDT - 7 months ago

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Jul 23, 2025, 8:03 AM EDT - 8 months ago

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Jul 15, 2025, 9:03 AM EDT - 8 months ago

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Jun 24, 2025, 9:03 AM EDT - 9 months ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Jun 16, 2025, 10:46 AM EDT - 9 months ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Jun 10, 2025, 9:03 AM EDT - 9 months ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Jun 3, 2025, 9:00 AM EDT - 10 months ago

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 28, 2025, 9:03 AM EDT - 10 months ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 20, 2025, 8:00 AM EDT - 10 months ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

May 14, 2025, 4:15 PM EDT - 10 months ago

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Enveric Biosciences Participating in BIO-Europe Spring®

Mar 17, 2025, 1:40 PM EDT - 1 year ago

Enveric Biosciences Participating in BIO-Europe Spring®

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Mar 6, 2025, 10:00 AM EST - 1 year ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Enveric Biosciences CEO Issues Letter to Shareholders

Feb 27, 2025, 9:30 AM EST - 1 year ago

Enveric Biosciences CEO Issues Letter to Shareholders

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Feb 25, 2025, 1:30 PM EST - 1 year ago

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Feb 4, 2025, 8:00 AM EST - 1 year ago

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Enveric Biosciences Announces Closing of $5 Million Public Offering

Feb 3, 2025, 5:00 PM EST - 1 year ago

Enveric Biosciences Announces Closing of $5 Million Public Offering

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Jan 30, 2025, 8:14 PM EST - 1 year ago

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Jan 30, 2025, 4:01 PM EST - 1 year ago

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Jan 6, 2025, 8:30 AM EST - 1 year ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Dec 2, 2024, 8:00 AM EST - 1 year ago

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Nov 25, 2024, 9:00 AM EST - 1 year ago

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Nov 14, 2024, 4:05 PM EST - 1 year ago

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Nov 12, 2024, 9:00 AM EST - 1 year ago

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Enveric Biosciences Announces Broad Range of Patent Issuances

Nov 4, 2024, 10:36 AM EST - 1 year ago

Enveric Biosciences Announces Broad Range of Patent Issuances

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Luckyjs38
Luckyjs38 Mar. 13 at 1:37 PM
$ENVB Its time to load up HODL IND filing imminent EB-003 is the way
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 11 at 8:48 PM
$ENVB lil tweak to u for later i
0 · Reply
Luckyjs38
Luckyjs38 Mar. 11 at 4:12 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Mar. 11 at 2:34 PM
$ENVB its time to load up in my opinion. trading at below its cash on hand to its equivalent market cap ⛓️‍💥🐦‍🔥♾️
0 · Reply
Luckyjs38
Luckyjs38 Mar. 10 at 3:17 PM
$ENVB Nows the time to load up and hold. I believe the IND filing will send it I know what I hold . do you ?
1 · Reply
Luckyjs38
Luckyjs38 Mar. 9 at 2:12 PM
$SPY $IWM $ENVB
0 · Reply
Luckyjs38
Luckyjs38 Mar. 9 at 1:56 PM
$SPY $IWM $ENVB ⛓️‍💥🐦‍🔥♾️ This company is extremely undervalued trading at a market cap of below cash on hand! My opinion EB-003 will change the medical science communities consensus on how to treat depression, anxiety,ptsd ect. 🇺🇸❤️🌎
0 · Reply
Luckyjs38
Luckyjs38 Mar. 6 at 10:03 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Mar. 6 at 7:55 PM
$ENVB @Enveric_Bio File the IND release the Kraken EB-003 LFG DR.TUCKER 🇺🇸
0 · Reply
topstockalerts
topstockalerts Mar. 6 at 2:23 PM
Pre Market Top Gainers $ASPC $ASPCU $ENVB $BEAT $HSPOU
0 · Reply
Luckyjs38
Luckyjs38 Mar. 5 at 2:05 PM
$ENVB $ABBV
0 · Reply
Luckyjs38
Luckyjs38 Mar. 5 at 2:05 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Mar. 5 at 2:05 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Mar. 5 at 1:49 PM
$ABBV You already know what we have $ENVB 🌎❤️
0 · Reply
Canna_1994
Canna_1994 Mar. 5 at 1:44 PM
$ENVB IND submission around the corner 🤑
0 · Reply
Lakeland_73
Lakeland_73 Mar. 4 at 4:21 PM
$ENVB Sold this trash and made 23% in 2 minutes with $CANF this morning
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 3 at 2:53 AM
$ENVB Current Stock Price: $2.22
0 · Reply
Lakeland_73
Lakeland_73 Mar. 3 at 12:30 AM
$ENVB Garbage
0 · Reply
Lakeland_73
Lakeland_73 Mar. 2 at 2:15 AM
$ENVB Overnight another plunge down
0 · Reply
Lakeland_73
Lakeland_73 Mar. 1 at 2:10 AM
$ENVB Yea and it’s crickets…
0 · Reply
Lakeland_73
Lakeland_73 Feb. 27 at 10:09 PM
$ENVB It’s got no chance
0 · Reply
Luckyjs38
Luckyjs38 Feb. 27 at 8:18 PM
$ENVB My prediction is we will see the IND filing in march and should get approval within about 30 days thereafter . the fda basically already gave them the green light to file with their last response .The start of stage 1 human trials EB-003 the God particle could be in Q2
0 · Reply